


























































1.1.	 Epidemiology	 of	 infections	 after	 open	
heart	surgery	
Open	heart	surgery	is	defined	as	any	type	of	surgery	performed	on	valves,	
arteries,	 or	 other	 heart	 structures,	 with	 the	 chest	 cut	 open.	 Despite	 its	
undoubted	benefits,	it	exposes	the	patient	to	some	potential	complications,	
such	 as	 cardiac	 dysfunction,	 mechanical	 complications,	 dysrhythmias,	
bleeding,	 thrombosis,	 and	 infections	 [3-5].	 Amongst	 others,	 the	
















access	 sites	 for	 cannulation.	 Superficial	 sternal	wound	 infections	 (SSWI),	
which	 are	 limited	 to	 the	 skin,	 subcutaneous	 tissue,	 and	pectoralis	 fascia,	
occur	more	frequently	than	deep	sternal	wound	infections	(DSWI)	(4-10%	
vs.	1-3%,	respectively),	which	reach	the	sternal	bone	and	the	mediastinum	
[15-17].	 Sternal	 wound	 infections	 develop	 especially	 in	 subjects	 with	
diabetes	 mellitus,	 obesity,	 hyperlipidemia,	 advanced	 age,	 and	 of	 female	
gender	 [16,	 18,	 19].	 The	 risk	 of	 DSWI,	 which	 is	 a	 much	 more	 severe	
complication	than	SSWI	being	often	associated	with	systemic	inflammatory	
response	and	reduced	survival	 [20-22],	 is	also	 increased	 in	patients	with	
prolonged	cardiopulmonary	bypass	 time,	nasal	colonization	by	S.	aureus,	
emergency	 or	 prolonged	 intervention,	 and	 sternal	 instability	 due	 to	
osteoporosis,	 radiotherapy	 or	 immunosuppression	 [21].	 Common	
causative	agents	of	SSWI	and	DSWI	include	mainly	Gram-positive	(mostly	S.	
aureus	and	coagulase-negative	staphylococci),	usually	responsible	for	more	
than	 70%	 of	 cases,	 and	 less	 frequently	 Gram-negative	 bacteria	 (mostly	
members	of	the	order	Enterobacterales	and	P.	aeruginosa)	[20,	22,	23].	As	
regards	 other	 types	 of	 surgical	 site	 infections,	 leg	wound	 infection	 after	
saphenous	vein	harvesting	occurs	in	1	to	3.5%	of	cardiac	surgery	patients,	
while	infection	of	access	sites	after	peripheral	cannulation,	percutaneous	or	




endocarditis	 (i.e.,	 developing	 within	 1	 year	 after	 valvular	 replacement)	
occurs	 in	 0.5-2%	 of	 cardiac	 surgery	 patients	 and	 is	 mostly	 caused	 by	
Staphylococcus	aureus	 or	 coagulative-negative	staphylococci	 [29-31].	The	
proportion	of	patients	with	postoperative	endocarditis	might	increase	to	3-
6%	at	5	years	from	valvular	replacement	[32].	However,	it	should	be	noted	
that	 prosthetic	 valve	 endocarditis	 developing	 at	 least	 1	 year	 after	 valve	




Postoperative	 urinary	 tract	 infections	 (UTI)	 develop	 in	 1-2%	 of	 patients	





the	 early	 postoperative	 period	 in	 intensive	 care	 unit	 (ICU)	 [14,	 36,	 37].	
Causative	 agents	 seem	 to	be	 equally	divided	between	Gram-positive	 and	
Gram-negative	 bacteria,	 although	 the	 possibility	 of	 postoperative	
candidemia	should	also	be	taken	into	account	in	patients	with	classical	risk	





infection,	 and	 the	 most	 frequent	 severe	 fungal	 infection	 developing	 in	
critically	ill	patients	in	ICU	[39-42]	.	Up	to	33-55%	episodes	of	candidemia	
have	been	estimated	to	occur	in	ICU	wards,	with	a	cumulative	incidence	of	
3.5-10	 episodes	 per	 1,000	 ICU	 admissions,	 with	 an	 increasing	 trend	
overtime	 [40,	 43-49].	 The	 most	 frequent	 Candida	 species	 causing	




caused	 by	 Gram-positive	 and	Gram-negative	 bacteria	 (43%	 vs.	 25%	 and	
29%,	respectively)	[45,	48].	Similar	results	were	found	in	the	observational,	
prospective,	 multicenter,	 EUROBACT	 study,	 conducted	 in	 162	 ICU	 in	 24	
countries,	28-day	mortality	of	candidemia	was	41%	vs.	34%	and	35%	in	
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bloodstream	 infections	 caused	 by	 Gram-positive	 and	 Gram-negative	
bacteria,	respectively	[50,	51].		






antibacterial	 therapy	 being	 the	most	 common	 clinical	 presentation	 [55].	
The	 use	 of	 laboratory	 tests	 for	 the	 diagnosis	 of	 candidemia	 is	 therefore	
fundamental	 and	 characteristically	 influenced	 by	 two	 therapeutic	
considerations.		








shown	 to	 have,	 conversely,	 an	 unacceptably	 high	 mortality	 without	
treatment	[56,	57].	Second,	candidemia	should	be	treated	promptly.	Indeed,	





has	 concomitantly	 100%	 sensitivity	 and	 100%	 specificity,	 and	 the	
turnaround	 time	 of	 the	 different	 test	 varies	 markedly.	 Consequently,	




blood	 cultures	 results),	 in	 order	 to	 maximize	 the	 overall	 diagnostic	
performance	 and	 guarantee	 as	much	 as	 possible	 both	 an	 early	 adequate	
therapy	in	patients	with	candidemia	and	the	safe	discontinuation	of	useless	
antifungals	in	those	with	no	fungal	infection.	
A	 possible	 diagnostic	 work-flow	 to	 be	 adopted	 in	 ICU	 patients	 with	
suspected	candidemia,	based	on	the	recent	suggestions	of	a	combined	task	
force	involving	the	systemic	inflammation	and	sepsis	and	infection	sections	
of	 the	 European	 Society	 of	 Intensive	 Care	 Medicine	 (ESICM)	 and	 the	
critically	 ill	 patients	 study	 group	 of	 European	 Society	 of	 Clinical	
Microbiology	and	Infectious	Diseases	(ESCMID)	[64],	is	shown	in	Figure	1,	
while	 a	 brief	 summary	 of	 the	 characteristics	 of	 laboratory	 tests	 for	 the	
diagnosis	of	candidemia	is	provided	in	Table	1.	
Figure 1. Possible diagnostic algorithm in ICU patients with suspected candidemia 
according to the combined task force of the systemic inflammation and sepsis and 
infection sections of ESICM and the critically ill patients study group of ESCMID [64] 
 
 
Modified from [64]. A-Mn, antimannan antibodies; BDG, (1,3)-β-D-glucan; CAGTA, C. 
albicans germ tube antigen; ESCMID, European Society of Clinical Microbiology and 
Infectious Diseases; ESICM, European Society of Intensive Care Medicine, ICU, 










A-Mn, antimannan antibodies; BDG, (1,3)-β-D-glucan; CAGTA, C. albicans germ tube 
antigen; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; Mn, 
mannan antigen; NPV, negative predictive value; PCR, polymerase chain reaction; PPV, 
positive predictive value. 
	
1.3.1.	Blood	cultures	
Although	 remaining	 the	 diagnostic	 reference	 standard	 for	 candidemia,	
blood	 cultures	 are	hampered	by	 their	 suboptimal	 sensitivity,	 usually	not	
higher	than	63-83%	[55,	65-69].	This	suboptimal	sensitivity	does	not	reflect	
the	 inability	of	blood	cultures	 to	detect	viable	Candida	 species,	but	more	
likely	 other	 factors,	 such	 as	 an	 intermittent/transient	 release	 of	 viable	
yeasts	in	the	bloodstream,	or	their	absence	in	the	captured	volume	of	blood	
Test Characteristics 
Blood cultures Allow identification at species level and susceptibility 
testing 
Suboptimal sensitivity 
Long turnaround time (reduced with MALDI-TOF 
technology) 
 




Mn/A-Mn Rapid turnaround time 
Variable performance across studies 
Reported low PPV 
 
CAGTA Rapid turnaround time 
Heterogeneous specificity 
Reported possible better performance in candidemia 
with deep-seated infection than without deep-seated 
infection 
 
PCR-based methods Rapid turnaround time 
Promising results of some newer methods 
Heterogeneity in the performance of first developed 
in-house and commercial methods 
Inability to detect all Candida species 
Usually expensive 
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Still,	 blood	 cultures	 remain	 essential	 within	 a	 comprehensive	 diagnostic	
approach,	as	they	allow	both	identification	of	Candida	at	the	species	level	





outside	 research	 laboratories	 [72-79])	 may	 be	 shortened	 by	 the	 use	 of	
matrix-assisted	 laser	 desorption/ionization	 time-of-flight	 (MALDI-TOF)	
technology	(with	>90%	accuracy)	[80,	81].	Huang	and	colleagues	reported	
that	the	use	of	MALDI-TOF	was	able	to	reduce	time	to	identification	from	84	





certain	 disease,	 can	 be	 used	 in	 two	 different	 ways:	 (i)	 before	 the	





As	 such,	 being	 based	 on	 readily	 available	 clinical	 and	 possibly	
microbiological	 (colonization)	 information,	 their	 usually	 high	 negative	
predictive	value	(NPV)	for	candidemia	allows	to	avoid,	since	the	onset	of	the	
disease,	 useless	 fungal	 diagnostics	 and	 antifungal	 treatments	 in	 patients	
 10 
unlikely	to	have	candidemia	(i.e.,	 those	with	 low	scores	according	to	risk	
prediction	models)	 [64].	Conversely,	 since	 their	positive	predictive	value	













colonization	 of	 non-sterile	 sites	 and/or	 on	 the	 intensity	 of	 Candida	
colonization	(dependent	of	 the	number	of	 colonized	sites)	 [85-87].	Some	
subsequent	prediction	models	are	conversely	based	exclusively	on	clinical	
variables	 and	 patients’	 medical	 history,	 and	 not	 on	 colonization.	 For	
example,	 predictive	 rules	 for	 the	 development	 of	 invasive	 candidiasis	
(including	not	only	candidemia	but	also	deep-seated	candidiasis)	in	surgical	
ICU	 patients	 have	 been	 developed	 by	 Paphitou	 and	 colleagues	 [88].	 The	
highest	risk	of	developing	proven	or	probable	invasive	candidiasis	(20%)	
was	 observed	 in	 patients	 with	 at	 least	 one	 among	 three	 possible	
predisposing	 factors	 (diabetes,	 total	 parenteral	 nutrition	 prior	 to	 ICU	
admission,	or	new	onset	haemodialysis)	plus	ICU	stay	longer	than	4	days,	
use	of	broad-spectrum	antibiotics,	and	no	use	of	antifungal	from	day	-7	to	
+3	 with	 respect	 to	 ICU	 admission	 [88].	 In	 another	 study	 conducted	 in	
cardiothoracic	 ICU	 patients,	 clinical	 variables	 that	 increased	 the	 risk	 of	
candidemia	 were	 ongoing	 mechanical	 ventilation	 ≥	 10	 days,	 hospital-
acquired	bacterial	infection,	cardiopulmonary	bypass	time	>	120	min,	and	





stay,	 plus	 at	 least	 two	 among	 surgery,	 immunosuppression,	 pancreatitis,	
total	parenteral	nutrition,	and	steroid	use	was	associated	with	a	10%	risk	









cumulative	 score	 of	 +8	 points	 [91].	 According	 to	 the	 Nebraska	 Medical	
Center	rule,	developed	in	a	cohort	of	352	ICU	patients,	a	NPV	of	99%	for	
invasive	 candidiasis	 may	 be	 obtained	 by	 employing	 a	 model	 based	 on	






(+1	 point),	 severe	 sepsis	 (+2	 points),	 and	 total	 parenteral	 nutrition	 (+1	
point).	 A	 score	 of	 >	 2.5	 points	was	 proposed	 as	 a	 cut-off	 for	 prompting	
empirical	 antifungal	 therapy	 based	 on	 a	 risk	 ratio	 of	 7.35	 [93].	 Finally,	
Playford	 and	 colleagues	 by	 using	 two	 threshold	 scores	 identified	 three	











The	 (1,3)-β-D-glucan	 (BDG)	 test	 is	 based	 on	 the	 detection	 of	 the	
polysaccharide	BDG	in	serum	[97,	98].	BDG	is	cell	wall	component	of	many	
pathogenic	fungi,	including	Candida	[97-99].		
The	 nearly	 pan-fungal	 nature	 of	 BDG	 might	 appear	 as	 an	 important	
limitation	 for	 using	 it	 as	 a	 diagnostic	 tool	 for	 candidemia	 in	 the	 ICU.	
However,	 it	 should	 be	 noted	 that	 the	 other	 two	most	 prevalent	 invasive	
fungal	diseases	(IFD)	in	ICU	patients	(and	less	frequent	than	candidemia)	
are	invasive	pulmonary	aspergillosis	and	Pneumocystis	jirovecii	pneumonia,	
in	 which	 serum	 BDG	 may	 well	 be	 positive,	 but	 often	 accompanied	 by	




candidemia,	 BDG	 showed	 high	NPV	 (>95%	 in	most	 studies),	 which	 thus	
makes	candidemia	unlikely	when	the	test	is	negative	[100-109].	It	should	
nonetheless	 be	 noted	 that	 a	 few	 clinical	 experiences	 have	 suggested	 a	
possible	 reduced	sensitivity	of	BDG	 for	candidemia	due	 to	C.	parapsilosis	
[101,	110,	111].	Therefore,	some	caution	in	discontinuing	antifungals	based	
on	a	negative	BDG	may	be	considered	in	centers	with	a	high	prevalence	of	
candidemia	due	to	C.	parapsilosis,	although	there	 is	also	a	need	 for	 large,	
prospective,	confirmatory	studies	to	definitely	confirm	this	hypothesis.	In	
contrast	with	this	high	NPV,	the	PPV	is	usually	low	(less	than	20%)	although	
it	may	 increase	with	 a	 second	 test	 as	 reported	 by	Martıń-Mazuelos	 and	
colleagues	 who	 found	 that	 BDG	 >	 80	 pg/mL	 in	 two	 consecutive	
measurements	had	a	PPV	of	35%	[112].	
A	disadvantage	of	the	BDG	test	reported	by	many	authors	is	its	suboptimal	




















We	 employed	 a	 desirability	 of	 outcome	 ranking	 (DOOR)	method	 (i.e.,	 to	
balance,	on	the	basis	of	blood	cultures	results,	the	hypothetical	benefits	and	
harms	 of	 using	 a	 BDG-based	 strategy	 for	 deciding	 whether	 or	 not	
administer	 early	 pre-emptive	 antifungals	 vs.	 using	 an	 universal	 strategy	
based	on	the	empirical	administration	to	all	patients	at	risk).	According	to	
the	 study	 results,	 the	BDG-based	 strategy	had	a	67.8%	probability	 (95%	
confidence	 intervals	 [CI]	 67.3–	 68.3)	 of	 prompting	 a	 “more	 desirable”	
therapeutic	 decision	 than	 the	 empirical	 strategy	 [132].	 However,	 we	
recognize	 that	 several	 important	 issues,	 including	 arbitrariness	 in	 the	
definition	of	the	ranked	outcome	and	in	the	interpretation	of	results	should	





conflicting,	or	perhaps,	 still	 incomplete	evidence.	 In	 the	EMPIRICUS	RCT,	
empirical	 and	 not	 pre-emptive	 therapy	 was	 evaluated,	 but	 some	
information	 regarding	 the	 possible	 usefulness	 of	 BDG	 testing	 can	 be	
garnered	from	the	subgroup	of	patients	with	positive	serum	BDG.	Indeed,	
fungal	infection-free	28-day	survival	in	ICU	patients	with	severe	sepsis	and	
positive	 serum	 BDG	 (>	 80	 pg/ml)	 was	 higher	 in	 BDG-positive	 patients	
treated	 with	 empirical	 micafungin	 (58/91,	 64%)	 than	 BDG-positive	
patients	receiving	placebo	(47/84,	56%),	with	a	trend	towards	a	potentially	
beneficial	 effect	 (hazard	 ratio	 [HR]	 1.41,	 95%	 CI	 0.85-2.23)	 [134].	
Conversely,	 a	 similar	 trend	 was	 not	 observed	 when	 the	 endpoint	 was	
limited	 to	 28-day	mortality	 (with	 or	without	 fungal	 infection)	 (HR	 0.95,	
95%	CI	 0.55-1.75)	 [134].	 In	 an	 unblinded,	 single-center	 RCT,	 Rouzé	 and	
colleagues	 assessed	 the	 percentage	 of	 early	 discontinuation	 for	 reasons	
other	than	death	in	patients	with	risk	factors	for	invasive	candidiasis	and	
receiving	empirical	antifungals	for	a	consistent	clinical	presentation	[135].	
Patients	 were	 randomized	 in	 two	 groups:	 (i)	 biomarker	 strategy	
(discontinuation	of	empirical	antifungals	in	case	of	negative	BDG,	mannan,	
and	antimannan	tests);	(ii)	routine	strategy	(14	days	of	therapy	in	patients	




were	 detected	 in	 subsequent	 probable/proven	 IC,	 subsequent	 antifungal	
treatments,	 length	of	ICU	stay,	and	mortality	[135].	Other	RCT	evaluating	
the	impact	of	BDG	results	on	early	therapeutic	choices	are	ongoing	or	have	
been	 recently	 completed	 (NCT02734550,	 NCT03117439,	 NCT03090334,	

















case-control	 study	 of	 43	 ICU	 patients	 with	 candidemia	 and	 67	 controls,	
Mn/A-Mn	 testing	 showed	 59%	 sensitivity	 and	 65%	 specificity	 for	 the	
diagnosis	of	candidemia	 [105].	 In	another	study	among	233	 ICU	patients	
with	severe	abdominal	conditions,	31	developed	 invasive	candidiasis	(11	
candidemia;	 20	 intra-abdominal	 candidiasis)	 [146].	 The	 diagnostic	
performances	of	Mn	and	A-Mn	were	evaluated	separately.	Mn	showed	43%	
sensitivity,	67%	specificity,	17%	PPV,	and	89%	NPV,	whereas	A-Mn	showed	
26%	 sensitivity,	 89%	 specificity,	 27%	 PPV,	 and	 89%	 NPV	 [146].	 In	 the	
previously	 cited	 RCT	 conducted	 by	 Rouzé	 and	 colleagues,	 decisions	
regarding	continuation	or	discontinuation	of	antifungals	were	based	on	a	
combination	of	BDG	and	Mn/A-Mn	testing,	but	their	separated	impact	was	
not	 evaluated	 [135].	 In	 the	 discussion,	 the	 authors	 reported	 that	 the	




The	C.	albicans	 germ	 tube	antigen	 (CAGTA)	 test	 is	 able	 to	detect	 specific	
antibodies	for	a	fungal	hyphal	protein	(namely,	Hwp1),	which	is	expressed	
by	Candida	 spp.	during	biofilm	 formation	and	 tissue	 invasion	 [151,	152].	
Although	 the	hyphal	protein	was	 initially	 found	 in	C.	albicans	 (hence	 the	
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the	diagnosis	 of	 IC	were	65%	 (95%	CI	 59-73)	 and	76%	 (95%	CI	 58-88)	








complexes,	 and	 low	 serum	 concentrations	 [160-168].	 Suboptimal	
performances	and	lack	of	standardization	are	also	important	limitations	of	





improve	 their	 usefulness	 in	 guiding	 pre-emptive	 therapeutic	 decisions.	
Martínez-Jiménez	and	colleagues	evaluated	the	combined	use	of	different,	









CAGTA	 [157].	 Subsequently,	 the	 same	 authors	 conducted	 a	 prospective	
study	in	which	they	measured	BDG	and	CAGTA	serum	levels	in	63	ICU	and	
37	 non-ICU	 patients	 receiving	 empirical	 antifungals	 in	 the	 suspicion	 of	
invasive	 candidiasis,	 to	 evaluate	 the	 potential	 for	 using	 the	 BDG/CAGTA	
combination	to	guide	safely	discontinuation	of	antifungals	when	both	the	
markers	are	negative	[154].	In	the	overall	study	population,	the	NPV	of	the	
combination	 was	 97%,	 reaching	 100%	 in	 the	 subgroup	 of	 ICU	 patients	
[154].	Another	experience	regarding	the	combined	use	of	BDG	and	CAGTA	
is	that	of	León	and	colleagues,	in	which	the	combination	(with	the	criterion	
for	 positivity	 being	 set	 to	 positivity	 of	 at	 least	 one	 of	 the	 two	markers)	
showed	90%	sensitivity,	42%	specificity,	19%	PPV,	and	97%	NPV	for	the	
diagnosis	of	invasive	candidiasis	in	233	ICU	patients	with	severe	abdominal	
conditions	 [146].	 A	 lower	 discriminatory	 ability	 was	 observed	 for	
combinations	involving	Mn	and/or	A-Mn	[146].	
With	 the	 aim	 of	 reducing	 costs	 of	 combined	 testing,	 and	 also	 to	 explore	
combinations	that	may	be	available	in	a	higher	number	of	laboratories,	we	
assessed	 the	performance	of	 serum	BDG	combined	with	 the	widely	used	
serum	procalcitonin	(PCT)	test	for	differentiating	between	candidemia	and	
bacteremia	 in	 a	 retrospective	 cohort	 of	 166	 ICU	 patients	 (73	 with	
candidemia	and	93	with	bacteremia)	[103].	The	rationale	was	based	on	the	
fact	that	serum	PCT	usually	remains	within	the	normal	concentration	range	
or	 is	 only	 slightly	 elevated	 in	 patients	with	 candidemia,	 differently	 form	
bacteremia,	 during	which	 high	 serum	PCT	 concentrations	 are	 frequently	
measured	[171-176].	Interestingly,	while	the	NPV	for	candidemia	observed	
by	combining	a	positive	BDG	with	low	PCT	levels	(<	2	ng/ml)	was	similar	to	
that	 of	 a	 positive	BDG	alone	 (95%	vs	93%,	 respectively),	 the	PPV	of	 the	
combination	was	considerably	higher	than	that	of	BDG	alone	(96%	vs.	79%,	





The	possibility	 of	 rapidly	 identify	Candida	 spp.	 in	 the	 blood	 or	 serum	of	
patients	 with	 candidemia	 by	 means	 of	 PCR-based	 techniques	 has	 been	
extensively	 studied	 in	 the	 last	 decades,	 prompted	 by	 the	 inherent	
advantages	 of	 increased	 sensitivity	 compared	 with	 blood	 cultures,	 very	
rapid	turnaround	time,	and	rapid	identification	at	species	level	[55,	151].	In	






Several	 studies	 have	 been	 recently	 published	 regarding	 the	 diagnostic	
performance	of	the	T2Candida	panel	(T2	Biosystems,	Lexington,	MA,	USA),	
which	is	FDA-cleared	for	the	diagnosis	of	candidemia.	The	test	is	based	on	
the	 mechanical	 lysis	 of	 cells,	 with	 subsequent	 amplification	 of	 DNA	 by	
means	of	PCR	and	target-specific	primers	(which	enable	the	identification	
of	 the	 5	 most	 frequent	 Candida	 species).	 The	 amplified	 products	 are	
detected	 by	 measuring	 the	 agglomeration	 of	 amplicons-induced	
supermagnetic	particles	[182,	183].	FDA	clearance	was	based	on	the	results	
of	 the	 DIRECT	 study,	 conducted	 in	 1801	 hospitalized	 patients	 in	 whom	
blood	cultures	were	ordered	according	to	local	standards	of	care	[183].	The	
T2Candida	panel	demonstrated	91%	sensitivity	(95%	CI	87-94)	and	99%	
specificity	 (99%-100%).	 The	 median	 time	 to	 positive	 results	 (including	
species	identification)	and	to	negative	results	was	4.4	±	1.0	hours	and	4.2	±	
0.9	hours,	 respectively.	A	99%	NPV	was	estimated	 for	a	population	with	
10%	 prevalence	 of	 candidemia	 [183].	 In	 a	 study	 conducted	 in	 126	 ICU	
patients	at	high	risk	of	invasive	candidiasis	and	with	sepsis	despite	3	days	
of	 broad-spectrum	 antibiotics,	 the	 sensitivity	 and	 specificity	 of	 the	
T2Candida	 panel	 for	 proven	 invasive	 candidiasis	 were	 55%	 and	 93%	
respectively,	 with	 50%	 PPV	 and	 93%	 NPV	 [184].	 In	 another	 study	
conducted	 among	 46	 patients	 with	 severe	 sepsis	 or	 septic	 shock	 and	
multiple	 risk	 factors	 for	 candidemia,	 the	T2Candida	panel	 showed	100%	
sensitivity	 (95%	 CI	 2.5-100),	 92%	 specificity	 (95%	 CI	 78-98),	 25%	 PPV	
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(95%	1-81),	and	100%	NPV	(95%	CI	90-100)	[185].	Of	note,	some	authors	
have	 also	 suggested	 that	 a	 positive	 T2Candida	 test	 could	 be	 a	 potential	
marker	of	poor	outcome	in	patients	receiving	empirical	antifungal	therapy	
for	 suspected	 invasive	 candidiasis	 [186].	 In	 the	 future,	 it	 is	 likely	 that	
cumulative	 evidenced	 from	 different	 real-life	 experiences	 will	 allow	 to	
precisely	 delineate	 the	 positioning	 of	 the	 T2Candida	 panel	 within	
diagnostic	 algorithms,	 and	 to	 maximize	 its	 cost-effectiveness	 (also	






initially	 inadequate	 therapies	 and	 for	 allowing	 safe	 de-escalation	 to	 oral	
azole	 therapy	 whenever	 indicated	 by	 the	 patient’s	 clinical	 conditions,	
although	it	should	be	noted	that	the	guidelines	of	 the	Infectious	Diseases	
Society	 of	 America	 (IDSA)	 recommend	 routine	 susceptibility	 testing	 for	
azole	 and	 echinocandin	 resistance	 in	 C.	 glabrata,	 while	 less	 value	 is	
attributed	to	routine	susceptibility	testing	of	other	Candida	species	[190].	
Some	 authors	 have	 nonetheless	 suggested	 that	 routine	 susceptibility	
testing	 of	 all	 Candida	 isolates	 from	 sterile	 sites	 could	 be	 important	 for	
registering	 resistance	 trends	 and	 for	 detecting	 the	 local	 emergence	 of	
resistance	 [75,	191].	 In	resource-limited	settings,	susceptibility	 testing	of	
Candida	 species	 may	 be	 limited	 to	 breakthrough	 infections,	 treatment	
failures,	or	in	presence	of	limited	therapeutic	options	[75,	191].		
Reference	 microbroth	 dilution	 methods	 suggested	 by	 the	 European	
Committee	 on	 Antimicrobial	 Susceptibility	 Testing	 [EUCAST]	 and	 the	
Clinical	 and	Laboratory	Standards	 Institute	 [CLSI],	 although	excellent	 for	
detecting	 resistance,	 are	 not	 easy	 to	 implement	 in	 routine	 laboratory	
workflows,	 in	 which	 the	 most	 frequently	 used	methods	 are	 commercial	
microbroth	dilution	tests,	semiautomated	broth	dilution,	and	agar	diffusion	
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[55].	 In	 the	 future,	 further	 development	 and	 validation	 of	 MALDI-TOF-
based	 detection	 of	 resistance	 could	 help	 reducing	 time	 to	 phenotypical	
susceptibility	 testing.	 As	 regards	 molecular	 methods,	 they	 may	 not	 be	
available	 in	many	laboratory,	and	have	the	 limitations	of	 identifying	only	
already	known	determinants	and	of	being	of	 little	use	for	detecting	azole	
resistance,	since	involved	genes	may	mutate	at	several	locations	[74,	192-








[203-205],	 ICU	 physicians	 may	 adopt	 an	 empirical	 approach	 relying	 on	
signs	 and	 symptoms,	 fungal	 biomarkers	 and	 specific	 risk	 factors	 for	
invasive	 candidiasis	 in	 the	 absence	 of	 any	 identified	 pathogen	 [206].	
Targeted	 therapy	 is	 based	 on	 microbiological	 evidence	 of	 an	 invasive	









for	 the	 treatment	 of	 candidemia	 are	 the	 echinocandins	 (caspofungin,	
micafungin,	 anidulafungin),	 azoles	 (fluconazole	 and	 voriconazole),	 and	




Table 2. Recommended adequate doses of antifungal drugs for empirical or targeted 
treatment of candidemia* 
Drugs Adequate dose Comment 
Caspofungin 70 mg loading dose followed by 50 mg daily Recommended as 
first line therapy [64, 
190, 209] 
Anidulafungin 200 mg loading dose followed by 100 mg daily 
Micafungin 100 mg daily. No loading dose is required 
Fluconazole 12 mg/kg loading dose followed by 6 mg/kg daily 
Recommended as an 
acceptable 
alternative to an 
echinocandin as 





therapy [64, 190, 
209] 
Voriconazole 3-4 mg/kg orally twice daily modified according to TDM 
Recommended for 
de-escalation 
therapy [64, 190, 
209] 
L-AmB 3 mg/kg daily 
Recommended as a 
reasonable 
alternative if there is 
intolerance, limited 
availability, or 
resistance to other 
antifungal agents 
[64, 190, 209] 
ABLC 5 mg/kg daily Not recommended 
ABCD 3- 4 mg/kg daily Not recommended 
L-AmB Liposomal amphotericin B; ABLC Amphotericin B lipid complex; ABCD 
Amphotericin B colloidal dispersion 
*Adequate doses refer to patients with normal renal and hepatic function and those 
with no drug-drug interactions.  
	
Caspofungin,	micafungin	 and	 anidulafungin	 are	 echinocandins	 for	which	
only	intravenous	formulation	is	available.	Echinocandins	target	the	fungal	
cell	wall	 and	act	by	 inhibiting	BDG	synthesis,	 showing	 fungicidal	 activity	
against	most	Candida	species	including	biofilms	forming	and	azole-resistant	
strains	 [210].	 Intrinsic	 resistance	 to	 echinocandins	 is	 anecdotal	 but	
acquired	resistance	has	been	increasingly	reported,	especially	in	C.	glabrata	
[211,	 212].	 In	 addition,	 echinocandins	 do	 not	 achieve	 therapeutically	
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effective	concentrations	in	some	tissues	(e.g.	eyes,	central	nervous	system	
[CNS],	 urine)	 and	 their	 pharmacokinetic/pharmacodynamic	 (PK/PD)	
properties	are	poorly	known	for	critically	ill	patients	[213].	




anidulafungin	 treatment	 resulted	 in	 superior	 combined	 clinical	 and	
microbiological	 response	 compared	 to	 fluconazole	 (at	 2	 weeks	 65%	 vs	
49%),	 although	no	differences	were	 observed	 for	 60-day	mortality	 rates	
[217].	 The	 use	 of	 echinocandins	 is	 further	 supported	 by	 a	 quantitative	
review	 of	 RCTs	 (1915	 patients,	 7	 studies)	 showing	 that	 treatment	 with	
echinocandins	 led	 to	 decreased	 mortality	 [odds	 ratio	 (OR)	 0.65;	 95%	
confidence	 interval	 (CI)	0.45,	0.94]	 and	 increased	 treatment	 success	 (OR	
2.33;	 95%	 CI	 1.27,	 4.35)	 [218].	 Moreover,	 a	 recent	 propensity	 score	




a	 prospective	 study	 conducted	 in	 29	 hospitals	 in	 Spain	with	 less	 severe	
patients	(only	30%	being	in	the	ICU),	empirical	treatment	with	fluconazole	
was	 not	 associated	 with	 increased	 30-day	 mortality	 compared	 with	
echinocandins	in	patients	with	candidemia	[207].	There	has	been	concern	
about	the	use	of	echinocandins	as	primary	therapy	against	C.	parapsilosis	
because	 of	 higher	 in	 vitro	 minimum	 inhibitory	 concentrations	 (MICs).	 A	










Azoles	 (fluconazole	 and	 voriconazole)	 work	 by	 inhibiting	 the	 14-alpha-
demethylase	 enzyme	 which	 mediates	 the	 conversion	 of	 lanosterol	 to	
ergosterol	 in	 the	 fungus	 wall.	 This	 class	 is	 metabolized	 by	 P450	
cytochromes,	 which	 can	 result	 in	 drug-drug	 interactions.	 Fluconazole	 is	




posaconazole,	 itraconazole	 and	 isavuconazole	 are	 not	 approved	 for	
systemic	Candida	infections.	
Amphotericin	B	is	a	polyene	that	acts	binding	to	the	ergosterol	in	the	fungal	
membrane.	 Owing	 to	 its	 toxicity,	 amphotericin	 B	 deoxycholate	 has	 now	
been	 replaced	 by	 better-tolerated	 polyenes	 including	 liposomal	
amphotericin	 B	 (L-AmB),	 amphotericin	 B	 lipid	 complex	 (ABLC)	 and	
amphotericin	B	colloidal	dispersion	(ABCD).	L-AmB	is	widely	used	and	has	
favorable	pharmacokinetics	along	with	high	intracellular	penetration	in	the	
cerebral	 spinal	 fluid	 and	 in	 the	 eye.	 Both	 L-AmB	 and	 ABLC	 achieve	
therapeutically	 effective	 concentrations	 in	 the	 epithelial	 lung	 fluid	 of	
critically	 ill	 patients	 [221].	 L-AmB	 is	 used	 as	 a	 first-line	 therapy	 for	
disseminated	 forms	 of	 Candida	 species	 infection,	 and	 as	 a	 second-line	
therapy	 for	 invasive	 candidiasis	 [213],	 especially	 when	 C.	 glabrata	
candidemia	from	urinary	tract	source	is	documented.		
A	few	more	antifungals	are	currently	under	investigation	for	the	treatment	
of	 candidemia	 and	 invasive	 candidiasis,	 including	 new	 compounds	
belonging	to	known	classes	or	molecules	with	novel	mechanisms	of	action	
[222].	Rezafungin	(previously	CD101)	is	a	novel	long-acting	echinocandin	
characterized	 by	 a	 spectrum	 of	 activity	 that	 is	 comparable	 to	 the	 other	
echinocandins	 but	 also	 a	 distinct	 safety	 PK/PD	 profile	 that	 enables	 high	
plasma	 drug	 exposure	 and	 extended	 interval	 dosing	 [223,	 224].	 In	 vitro,	
rezafungin	 has	 demonstrated	 potent	 activity	 against	 a	 broad	 range	 of	
Candida	spp.,	including	echinocandin-	and	azole-resistant	strains	[225],	but	
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interlaboratory	 variation	 was	 observed	 thus	 warranting	 further	
investigation	[226].	A	multicentre,	randomized,	double-blind	phase	2	trial	
evaluating	the	efficacy	and	safety	of	rezafungin	once	weekly	compared	with	
caspofungin	 in	 patients	 with	 candidemia	 has	 been	 recently	 finished	
(NCT023734682).	
SCY-078	 is	 a	 semisynthetic,	 triterpenoid,	 antifungal	 glucan	 synthase	
inhibitor,	 currently	 in	 development	 for	 the	 treatment	 of	 invasive	 and	
mucocutaneous	 fungal	 diseases	 [227].	 SCY-078	 has	 shown	 good	
bioavailability	and	has	been	studied	as	oral	and	intravenous	formulations	







candidiasis	 without	 clinical	 signs	 or	 symptoms	 of	 infection	 [190,	 202].	
Although	 the	 benefits	 of	 antifungal	 prophylaxis	 are	 well	 established	 in	
neutropenic	 patients	 (e.g.	 haematological	 patients)	 or	 in	 solid	 organ	




Over	 the	 last	 decade,	 several	 studies	 [229-232]	 have	 focused	 on	 the	
prevention	 of	 fungal	 infections	 in	 ICU	 patients	 administering	
echinocandins,	 azoles	 and	 oral	 nystatin.	 Despite	 the	 large	 number	 of	
publication,	 the	 quality	 of	 evidence	 still	 remains	 low	 in	 many	 studies,	
leading	to	uncertainty	with	regard	to	the	reduction	of	mortality,	reduction	
of	invasive	candidiasis,	or	the	risks	of	fungal	colonization	[229].	Since	the	
universal	 administration	of	 antifungal	 prophylaxis	 remains	 an	 inefficient	
















based	 on	 risk	 factors,	 positive	 culture	 collected	 from	 non-sterile	 sites	
(respiratory	tract,	urine),	clinical	scoring	systems	and	surrogate	markers	of	
infection.	






study	 performed	 in	 36	 ICUs,	 antifungal	 treatment	 was	 empirically	
administered	 according	 to	 Candida	 score	 to	 180	 out	 of	 1,017	 patients	
included	 in	 the	 study	 (17%),	 but	 only	 5%	 of	 those	 really	 developed	
candidemia	[238].	
Surrogate	markers	that	have	been	evaluated	in	critically	ill	patients	include	












Limited	 clinical	 studies	have	 evaluated	 the	 efficacy	of	 empiric	 strategies.	
Three	 multicenter	 randomized	 clinical	 trials	 [84,	 134,	 237]	 evaluated	
empirical	 antifungal	 therapy	 for	 fungal	 infection	 suspicion	 in	 high	 risk	




prospective	 randomized	multicenter	 trial	 including	260	non-neutropenic	
critically	 ill	 patients	 with	 ICU-acquired	 sepsis,	 multiple	 Candida	
colonization	and	multi-organ	failure.	Although	empirical	use	of	micafungin	
was	associated	with	a	 lower	 rate	of	new	 IFD	diagnosis	 in	 comparison	 to	
placebo	(4/128	patients	[3%]	vs	15/123	[12%];	p	=	 .008),	there	were	no	
differences	 between	 the	 two	 arms	 regarding	 death	 and	 invasive	 fungal	
disease-free	at	28	days	(hazard	ratio,	1.35	[95%	CI,	0.87-2.08]).	
Despite	 these	 results,	 the	 fact	 is	 that	 the	 empirical	 approach	 remains	 a	
common	practice	both	inside	and	outside	ICU	[186]	and	its	role	in	high-risk	






lower	 respiratory	 tracts,	 skin	 folds,	 drains,	 operative	 site)	 with	 proven	
Candida	species	colonization	[64].	
Once	 empirical	 treatment	 is	 started,	 an	 echinocandin	 regimen	 should	 be	
preferred	 especially	 in	 hemodynamically	 unstable	 patients	 or	 those	
previously	exposed	to	an	azole,	and	in	those	colonized	with	azole-resistant	
Candida	 species	[64].	Daily	clinical	revaluation	should	be	performed,	and	
treatment	 should	 be	 stopped	 earlier	 (within	 4-5	 days	 of	 antifungal	
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infection	 with	 an	 echinocandin	 (e.g.	 caspofungin,	 anidulafungin	 or	
micafungin),	 rather	 than	 fluconazole.	 Evidences	 supporting	 this	
recommendation	 are	 mainly	 based	 on	 the	 increasing	 prevalence	 of	
fluconazole-resistant	 Candida	 spp.	 [202,	 244,	 245]	 and	 from	 previously	
described	 clinical	 trials	 in	 which	 echinocandins	 showed	 a	 significantly	
higher	 efficacy	 in	 comparison	 to	 azoles	 for	 the	 treatment	 of	 candidemia	















has	 no	 impact	 survival	 [246]	 and	 has	 been	 associated	with	 a	 significant	
decrease	in	antifungal	use	[243],	recent	studies	showed	that	only	20-40%	







to	 systematically	 perform	 a	 transoesophageal	 echocardiography	 and	
fundoscopy	 to	 all	 patients	 with	 a	 positive	 blood	 culture	 [64,	 190,	 209],	
irrespective	 of	 clinical	 signs	 or	 symptoms	 of	 metastatic	 infection	 or	






Source	 control	 includes	 all	 measures	 to	 control	 invasive	 infection	 (i.e	









abdominal	 infection	 [243]	 or	 those	 with	 a	 candidemia	 from	 urinary	
tract217.	Importantly,	physicians	should	always	keep	in	mind	that	efficacy	






















example,	 the	 possible	 influence	 of	 cardiac	 surgery-related	 factors	 on	 the	
risk	of	postoperative	candidemia	has	been	previously	addressed,	although	
with	non	univocal	results	[38,	89].	
To	 add	 to	 the	 literature	 and	 nurturing	 the	 discussion	 on	 this	 topic,	 we	
conducted	a	multicenter	case-control	study	in	seven	hospitals	in	Italy.	Our	













time	 at	 risk.	 For	 cases,	 time	 at	 risk	 was	 defined	 as	 the	 number	 of	 days	
elapsed	from	surgery	to	the	onset	of	candidemia	(i.e.,	the	day	when	the	first	






The	 primary	 study	 endpoint	 was	 development	 of	 candidemia.	 Crude	
mortality	 within	 30	 days	 after	 the	 onset	 of	 candidemia	 in	 cases	 was	 a	





The	 following	 baseline	 data	 (pre-operative	 and	 peri/intraoperative	
variables)	 were	 retrospectively	 collected	 from	 medical	 records	 and	
laboratory	databases	of	 the	participating	hospitals:	age;	gender;	diabetes	
(defined	 as	 any	 preoperative	 diagnosis	 of	 diabetes	 mellitus	 requiring	
treatment);	 New	 York	 Heart	 Association	 (NYHA)	 class	 of	 heart	 failure;	
chronic	 kidney	 disease	 (defined	 as	 history	 of	 serum	 creatinine	 >200	
mmol/L);	 chronic	 obstructive	pulmonary	disease	 (COPD,	defined	as	 long	
term	 use	 of	 bronchodilators	 or	 steroids	 for	 lung	 disease);	 history	 of	
immunosuppression	(defined	as	one	or	more	of	the	following:	solid	organ	
transplantation;	 malignancy;	 neutropenia	 [absolute	 neutrophil	 count	






intervention	 on	 the	 abdominal	 aorta,	 carotids	 or	 limb	 arteries);	
preoperative	stroke	(defined	as	any	focal	or	global	neurological	syndrome	
caused	 by	 ischemia	 or	 hemorrhage	 not	 resolving	within	 24	 h);	 previous	
acute	 myocardial	 infarction	 (within	 3	 months);	 left	 ventricular	 ejection	
fraction	 (LVEF);	 EuroSCORE	 II	 [257];	 type	 of	 open	 heart	 surgery	
(categorized	as	isolated	coronary	artery	bypass	surgery,	isolated	valvular	
surgery,	 surgery	 of	 thoracic	 aorta,	 or	 other/combined	 procedures);	





for	 candidemia	 in	 both	 cases	 and	 controls	 (postoperative	 variables):	
presence	 of	 central	 venous	 catheter	 for	 >48	 hours;	 receipt	 of	 total	
parenteral	 nutrition	 for	 >48	 hours;	 hemodialysis	 therapy	 for	 >48	 hours;	
administration	 of	 broad-spectrum	 antibiotics	 for	 >48	 hours;	 Candida	
colonization	(defined	as	isolation	of	Candida	spp.	from	non-sterile	sites	in	




The	 following	 data	 were	 also	 collected	 for	 cases	 (candidemia-related	
variables):	species	of	Candida	isolated	from	blood;	presence	of	septic	shock	
at	the	time	of	candidemia	(according	to	Sepsis-3	criteria	[259]),	removal	of	
central	 venous	 catheter	 within	 48	 hours	 after	 the	 onset	 of	 candidemia,	













the	 development	 of	 candidemia	 after	 open	 heart	 surgery.	 To	 this	 aim,	
demographic	and	clinical	 variables	were	 first	 tested	 for	 their	 association	
with	 the	dependent	variable	 (development	of	candidemia)	 in	univariable	
conditional	logistic	regression	models	for	matched	pairs/sets,	with	strata	
composed	 by	 sets	 of	 single	 cases	 and	 their	 two	matched	 controls	 [260].	
Then,	 variables	 associated	 with	 the	 development	 of	 candidemia	 in	
univariable	comparisons	(p	<0.05)	were	included	in	an	initial	multivariable,	
conditional	 logistic	 regression	model	 for	matched	pairs/sets,	and	 further	
selected	for	the	final	multivariable	model	by	means	of	a	stepwise	backward	
procedure.	 A	 secondary	 study	 analysis	 was	 the	 identification	 of	 factors	
associated	with	crude	30-day	mortality	in	candidemia	cases.	To	this	aim,	we	
employed	 univariable	 and	multivariable	 comparisons	 as	 for	 the	 primary	
analysis,	 with	 the	 exception	 of	 using	 unconditional	 logistic	 regression	




Overall,	 222	 patients	 were	 included	 in	 the	 study	 (74	 cases	 and	 148	






During	 the	 study	 period,	 36,476	 open-heart	 surgery	 procedures	 were	
performed	 in	 the	 participating	 centers.	 The	 cumulative	 incidence	 of	
postoperative	candidemia	over	the	study	period	was	of	2.03	episodes	per	








Table	 1	 shows	 the	 results	 of	 univariable	 and	 multivariable	 analyses	 of	
factors	 associated	 with	 the	 development	 of	 candidemia.	 In	 univariable	
analysis,	NYHA	class	equal	or	greater	than	III,	previous	stroke,	 low	LVEF,	
preoperative	 MV,	 higher	 EuroSCORE	 II	 score,	 preoperative	 mechanical	
ventilation,	 hemodialysis	 therapy,	 SOFA	 score	 at	 the	 time	 of	 surgery,	
previous	 therapy	 with	 cephalosporins,	 previous	 therapy	 with	
carbapenems,	 previous	 therapy	 with	 fluoroquinolones,	 and	 multifocal	










30-day	 mortality	 in	 patients	 with	 candidemia	 are	 shown	 in	 table	 2.	 In	
univariable	 analysis,	 >5	 peri/intraoperative	 blood	 transfusions,	 previous	
therapy	with	fluoroquinolones,	and	septic	shock	at	the	onset	of	candidemia	
were	 associated	 with	 increased	 30-day	 mortality.	 Only	 septic	 shock,	




Table 1. Univariable and multivariable analyses of factors associated with the development of candidemia after open heart surgery 
   Univariable analysis Multivariable analysis* 
Variable No. of cases (%) 
 74 (100) 
No. of controls (%) 
 148 (100) 
Odds ratio 
(95% CI) 
P Odds ratio 
(95% CI) 
P 
       
Age in years, median (IQR) 72 (64-78) 72 (64-77) 1.00 (0.98-1.03) 0.932   
Male gender 41 (55) 99 (67) 0.64 (0.37-1.11) 0.113   
Diabetes mellitus 23 (31) 29 (20) 1.80 (0.96-3.39) 0.067   
NYHA class III/IV 53 (72) 40 (27) 6.26 (3.21-12.21) <0.001 23.81 (5.73-98.95) <0.001 
Chronic kidney disease 29 (39) 42 (28) 1.63 (0.90-2.95) 0.105   
COPD 22 (30) 36 (24) 1.34 (0.70-2.56) 0.372   
History of immunosuppression 1 (1) 9 (6) 0.20 (0.02-1.64) 0.133   
Charlson score, median (IQR) 5 (3-7) 5 (3-6) 1.08 (0.95-1.23) 0.232   
Peripheral vascular disease 14 (19) 27 (18) 1.04 (0.52-2.10) 0.905   
Previous stroke 12 (16) 8 (5) 4.00 (1.38-11.57) 0.010 4.61 (0.68-31.28) 0.118 
Previous IMA 13 (18) 31 (21) 0.83 (0.42-1.62) 0.577   
LVEF (%), median (IQR) 50 (37-55) 55 (45-55) 0.97 (0.95-1.00) 0.031 - 0.633 
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EuroSCORE II 6.61 (3.67-16.43) 3.51 (1.86-8.37) 1.06 (1.02-1.10) 0.001 - 0.177 
Preoperative MV 16 (22) 9 (6) 3.56 (1.57-8.05) 0.002 - 0.275 
Type of surgery    0.073   
    Isolated coronary artery bypass surgery  6 (8) 22 (15) (ref)    
    Isolated valvular surgery 32 (43) 48 (32) 2.43 (0.88-6.71)    
    Surgery of thoracic aorta 26 (35) 41 (28) 2.13 (0.78-5.82)    
    Other/mixed procedures 10 (14) 37 (25) 0.93 (0.29-2.97)    
Pacemaker implantation 2 (3) 10 (7) 0.40 (0.09-1.83) 0.237   
CPB time (minute), median (IQR) 136 (98-208) 136 (92-197) 1.00 (1.00-1.00) 0.843   
Aortic cross-clamp time (minute), median (IQR) 75 (49-120) 87 (58-120) 1.00 (0.99-1.00) 0.127   
SOFA score at time of surgery, median (IQR) 4 (1-7) 3 (0-4) 1.19 (1.07-1.34) 0.002 1.20 (0.99-1.45) 0.058 
Need for peri/intraoperative blood transfusion 61 (82) 124 (84) 0.85 (0.33-2.22) 0.854   
Need for >5 peri/intraoperative blood transfusions 47 (64) 86 (58) 1.56 (0.69-3.52) 0.288   
Central venous catheter >48 h 74 (100) 141 (95) (model not converging) -   
Total parenteral nutrition >48 h 42 (57) 86 (58) 0.94 (0.50-1.74) 0.833   
Hemodialysis >48 h 27 (37) 28 (19) 2.55 (1.32-4.91) 0.005 - 0.566 
Previous therapy with cephalosporins >48 h 18 (24) 12 (8) 4.65 (1.81-11.94) 0.001 - - 
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Previous therapy with carbapenems >48 h 52 (70) 51 (35) 4.49 (2.37-8.49) <0.001 8.87 (2.57-30.67) 0.001 
Previous therapy with fluoroquinolones >48 h 49 (66) 51 (35) 5.78 (2.64-12.65) <0.001 5.73 (1.61-20.41) 0.007 
Candida colonization 29 (39) 45 (30) 1.52 (0.83-2.80) 0.178   
Candida multifocal colonization (at least 2 sites) 19 (26) 14 (10) 2.95 (1.43-6.12) 0.004 - 0.723 
Bacterial BSI** 23 (31) 38 (26) 1.30 (0.69-2.47) 0.415   
Results are presented as n (%) unless otherwise indicated. BSI, bloodstream infection; CI, confidence intervals; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; 
IMA, acute myocardial infarction; IQR, Interquartile range; LVEF, left ventricular ejection fraction; MV, mechanical ventilation; NYHA, New York Hearth Association. 
* Odds ratio and 95% CI presented only for variable retained in the final multivariable model. 
** Coagulase-negative staphylococci (n = 24); Klebsiella spp. (n = 8); Staphylococcus aureus (n = 6); Enterobacter spp. (n = 3); Pseudomonas spp. (n = 3); Enterococcus spp. (n = 2); other 











Table 2. Univariable and multivariable analyses of factors associated with 30-day mortality in patients with candidemia 
   Univariable analysis Multivariable analysis* 
Variable Non-survivors (%) 
 39 (100) 
Survivors (%) 
 35 (100) 
Odds ratio 
(95% CI) 
P Odds ratio 
(95% CI) 
P 
       
Age in years, median (IQR) 75 (67-79) 68 (60-76) 1.03 (0.99-1.08) 0.129   
Male gender 21 (54) 20 (57) 0.88 (0.35-2.19) 0.776   
Diabetes mellitus 11 (28) 12 (34) 0.75 (0.28-2.02) 0.573   
NYHA class III/IV 29 (74) 24 (69) 1.33 (0.48-3.66) 0.582   
Chronic kidney disease 17 (44) 12 (34) 1.48 (0.58-3.80) 0.414   
COPD 12 (31) 10 (29) 1.11 (0.41-3.02) 0.836   
History of immunosuppression 1 (3) 0 (0) (model not converging) -   
Charlson score, median (IQR) 5 (3-7) 5 (2-6) 1.09 (0.90-1.32) 0.390   
Peripheral vascular disease 7 (18) 7 (20) 0.88 (0.27-2.80) 0.822   
Previous stroke 7 (18) 5 (14) 1.31 (0.38-4.59) 0.670   
Previous IMA 10 (26) 3 (9) 3.68 (0.92-14.69) 0.065   
LVEF (%), median (IQR) 50 (35-55) 48 (39-55) 1.00 (0.96-1.04) 0.984   
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EuroSCORE II 13.57 (4.07-21.93) 4.57 (3.43-10.34) 1.05 (1.00-1.10) 0.052   
Preoperative MV 10 (26) 6 (17) 1.67 (0.54-5.19) 0.378   
Type of surgery    0.898   
    Isolated coronary artery bypass surgery  4 (10) 2 (6) (ref)    
    Isolated valvular surgery 16 (41) 16 (46) 0.50 (0.08-3.13)    
    Surgery of thoracic aorta 14 (36) 12 (34) 0.58 (0.09-3.76)    
    Other/mixed procedures 5 (13) 5 (14) 0.50 (0.06-4.09)    
Pacemaker implantation 1 (3) 1 (3) 0.90 (0.05-14.86) 0.938   
CPB time (minute), median (IQR) 136 (98-198) 137 (93-213) 1.00 (1.00-1.00) 0.652   
Aortic cross-clamp time (minute), median (IQR) 73 (51-110) 89 (49-140) 1.00 (0.99-1.01) 0.603   
SOFA score at time of surgery, median (IQR) 4 (1-7) 3 (1-6) 1.02 (0.89-1.17) 0.749   
Need for peri/intraoperative blood transfusion 32 (82) 29 (83) 0.95 (0.29-3.14) 0.928   
Need for >5 peri/intraoperative blood transfusions 29 (74) 18 (51) 2.74 (1.03-7.28) 0.043 - 0.151 
Central venous catheter >48 h 39 (100) 35 (100) - -   
Total parenteral nutrition >48 h 25 (64) 17 (49) 1.89 (0.75-4.80) 0.180   
Hemodialysis >48 h 16 (41) 11 (31) 1.52 (0.58-3.95) 0.393   
Previous therapy with cephalosporins >48 h 10 (26) 8 (23) 1.16 (0.40-3.38) 0.781   
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Previous therapy with carbapenems >48 h 26 (67) 26 (74) 0.69 (0.25-1.90) 0.475   
Previous therapy with fluoroquinolones >48 h 30 (77) 19 (54) 2.81 (1.03-7.62) 0.043 - 0.115 
Candida colonization 13 (33) 16 (46) 0.59 (0.23-1.52) 0.278   
Candida multifocal colonization (at least 2 sites) 9 (23) 10 (29) 0.75 (0.26-2.13) 0.590   
Bacterial BSI** 9 (23) 14 (40) 0.45 (0.17-1.23) 0.120   
Septic shock 21 (54) 6 (17) 5.64 (1.91-16.63) 0.002 5.64 (1.91-16.63) 0.002 
Causative Candida species    0.184   
    albicans 28 (74) 20 (59) (ref)    
    Non-albicans*** 10 (26) 14 (41) 0.51 (0.19-1.38)    
Early antifungal therapy (within 48 h****) 13 (33) 16 (46) 0.59 (0.23-1.52) 0.278   
Early CVC removal (within 48 h****) 13 (33) 14 (40) 0.75 (0.29-1.94) 0.552   
Results are presented as n (%) unless otherwise indicated. BSI, bloodstream infection; CI, confidence intervals; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; 
CVC, central venous catheter; IMA, acute myocardial infarction; IQR, Interquartile range; LVEF, left ventricular ejection fraction; MV, mechanical ventilation; NYHA, New York Hearth 
Association. 
* Odds ratio and 95% CI presented only for variable retained in the final multivariable model. 
** Coagulase-negative staphylococci (n = 8); Klebsiella spp. (n = 5); Pseudomonas spp. (n = 3); Staphylococcus aureus (n = 2); other bacteria with lower frequencies (n = 5) 
*** 2 non-typed species not included in the comparison albicans vs. non-albicans species. Typed non-albicans species were as follows: C. parapsilosis (n = 10); C. glabrata (n = 7); C. 
tropicalis (n = 3); C. krusei (n = 2); C. dubliniensis (n = 1); C. sake (n = 1). 
**** After the onset of candidemia (i.e., the day when the first positive blood culture for Candida spp. was draw
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2.4.	Discussion	
In	 this	 retrospective,	 multicenter,	 case-control	 study,	 high	 NYHA	 class,	
previous	 therapy	 with	 carbapenems,	 and	 previous	 therapy	 with	






Controls	 were	 matched	 to	 cases	 according	 to	 gender,	 body	 mass	 index,	
agents	administered	for	general	anesthesia	and	for	postoperative	sedation,	
type	of	employed	cardioplegia,	and	CPB	technique.	Independent	predictors	
of	 candidemia	 were	 MV	 >10	 days,	 hospital-acquired	 bacterial	 infection	





and	 high	 simplified	 acute	 physiology	 score	 (SAPS	 II),	 whereas	 no	
association	with	development	 of	 candidemia	was	 observed	 for	 CPB	 time	
[38].	
A	necessary	premise	that	should	be	made	before	comparing	the	results	of	
these	 two	 studies	with	 those	of	our	 study	 is	 that	 the	design	of	 the	 three	
studies	 (case-control	 vs.	 cohort,	 type	 of	 matching	 criteria)	 was	 very	
different	 across	 the	 three	 experiences.	 This	 is	 not	 necessarily	 a	
disadvantage,	 since	 in	 our	 opinion,	 it	 allows	 to	 address	 the	 topic	 from	
different,	complementary	perspectives.	For	example,	similar	to	Pasero	and	
colleagues,	 we	 did	 not	 find	 an	 association	 between	 prolonged	 CPB	 and	
development	of	postoperative	candidemia.	However,	it	should	be	noted	that	
CPB	time	was	higher	in	patients	with	candidemia	than	in	patients	without	
candidemia	 in	 the	 study	 of	 Pasero	 and	 colleagues	 (mean	 178	 vs.	 149	
minutes,	 respectively),	 thus	 the	 absence	 of	 a	 statistically	 significant	











to	 explicitly	 focus	 on	 a	 population	 of	 cardiac	 surgery	 patients	 with	 a	
prolonged	 length	 of	 stay,	 that	 is,	 on	 those	 patiens	 in	 whom	 the	 risk	 of	








(i)	 further	 studies	may	 be	 necessary	 to	 confirm	whether	 prolonged	 CPB	
time	 could	 be	 a	 predictor	 for	 early	 candidemia	 after	 cardiac	 surgery;	 (i)	
prolonged	 CPB	 time	 may	 not	 be	 helpful	 for	 discriminating	 the	 risk	 of	
candidemia	(absolutely	or	vs.	that	of	bacterial	BSI	[262])	in	cardiac	surgery	
patients	with	prolonged	ICU	stay.	
With	 regard	 to	 independent	 predictors,	 our	 results	 confirm	 that	 the	
previous	 administration	 of	 broad	 spectrum	 antibiotics	 is	 an	 important	
predictor	 of	 candidemia	 in	 cardiac	 surgery	 patients	 with	 prolonged	
postoperative	ICU	stay,	in	line	with	results	of	studies	conducted	in	general	
ICU	populations	 [88,	90-92].	 In	addition,	we	 found	a	high	baseline	NYHA	
class	 to	 be	 an	 independent	 predictor	 of	 postoperative	 candidemia.	 This	
finding	warrants	 further	 investigation,	since	this	predisposing	 factor	was	




may	 represent	 a	proxy	 for	 a	 higher	burden	of	 comorbidity,	 possibly	 and	
generally	influencing	the	risk	of	postoperative	infections.	
Finally,	as	a	secondary	analysis,	we	also	assessed	the	predictors	of	30-day	
mortality	 in	 patients	 with	 postoperative	 candidemia.	 In	 this	 regard,	 the	
independent	association	we	observed	between	septic	shock	and	mortality	
further	confirms	the	importance	of	the	severity	of	clinical	presentation	in	
unfavorably	 influencing	 the	 outcome	 [49].	 On	 the	 other	 hand,	 caution	 is	
needed	before	interpreting	the	absence	of	other	independent	predictors	in	
our	 analysis	 as	 the	 absence	 of	 other	 associations	 that	 could	 be	 clinically	
relevant.	For	example,	early	antifungal	therapy	and	early	CVC	removal	have	
been	 previously	 indicated	 as	 important	 predictors	 of	 survival,	 and	 it	 is	
worth	noting	that	a	trend	towards	improved	survival	for	these	two	factors	
was	 also	 appreciable	 in	 our	 univariable	 results,	 although	 not	 reaching	
statistically	 significance	 (possibly	 because	 of	 the	 reduced	 power	 of	 our	
secondary	analysis).	
This	study	has	some	important	limitations.	The	most	important	are	related	
to	 its	 retrospective	 nature,	 and	 mainly	 consisting	 in	 information	 biases		




that	 may	 have	 influenced	 the	 risk	 of	 infection).	 Two	 other	 important	
limitations	are	the	lack	of	long-term	follow-up	in	survivors	of	candidemia	
26	and	 the	use	of	 a	 single	 control	 group	 instead	of	 two	different	 control	
groups	to	separately	assess	(i)	the	predictors	of	candidemia	vs.	no	infection	
and	 (ii)	 the	 predictors	 of	 candidemia	 vs.	 bacteremia.	 Finally,	 although	









class	 were	 independent	 predictors	 of	 candidemia	 in	 cardiac	 surgery	
patients	 with	 prolonged	 postoperative	 ICU	 stay,	 whereas	 no	 association	
between	prolonged	CPB	time	and	candidemia	was	observed	in	the	present	
case-control	study.	Further	studies	are	needed	to	explore	the	possible	role	
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